USD 84.74
(-0.94%)
Year | Eps | Eps Growth |
---|---|---|
2023 | 1.98 USD | 201.43% |
2022 | 0.70 USD | -9.09% |
2021 | 0.77 USD | 170.64% |
2020 | -1.09 USD | 18.66% |
2019 | -1.34 USD | -191.3% |
2018 | -0.46 USD | -188.46% |
2017 | 0.52 USD | 248.57% |
2016 | -0.35 USD | -157.38% |
2015 | 0.61 USD | 0.0% |
Year | Eps | Eps Growth |
---|---|---|
2024 Q2 | 0.45 USD | -10.0% |
2024 Q1 | 0.50 USD | -45.05% |
2023 Q2 | 0.34 USD | -5.56% |
2023 Q4 | 0.91 USD | 127.5% |
2023 Q3 | 0.40 USD | 17.65% |
2023 Q1 | 0.36 USD | 280.0% |
2023 FY | - USD | 201.43% |
2022 Q4 | -0.20 USD | -183.33% |
2022 FY | - USD | -9.09% |
2022 Q3 | 0.24 USD | -20.0% |
2022 Q1 | 0.34 USD | 21.43% |
2022 Q2 | 0.30 USD | -11.76% |
2021 Q1 | 0.17 USD | -10.53% |
2021 Q3 | 0.00 USD | -98.68% |
2021 FY | - USD | 170.64% |
2021 Q4 | 0.28 USD | 6729.27% |
2021 Q2 | 0.31 USD | 82.35% |
2020 Q4 | 0.19 USD | 163.33% |
2020 Q1 | -0.12 USD | 36.84% |
2020 Q2 | -0.86 USD | -616.67% |
2020 Q3 | -0.30 USD | 65.12% |
2020 FY | - USD | 18.66% |
2019 Q4 | -0.19 USD | -35.71% |
2019 Q2 | -0.80 USD | -263.64% |
2019 Q1 | -0.22 USD | 33.33% |
2019 FY | - USD | -191.3% |
2019 Q3 | -0.14 USD | 82.5% |
2018 Q2 | 0.03 USD | -44.75% |
2018 FY | - USD | -188.46% |
2018 Q4 | -0.33 USD | 21.43% |
2018 Q3 | -0.42 USD | -1500.0% |
2018 Q1 | 0.05 USD | 0.0% |
2017 Q4 | - USD | 0.0% |
2017 FY | - USD | 248.57% |
2016 FY | - USD | -157.38% |
2015 FY | - USD | 0.0% |
Name | Eps | Eps Difference |
---|---|---|
AptarGroup, Inc. | 4.34 USD | 54.378% |
Baxter International Inc. | 5.25 USD | 62.286% |
Becton, Dickinson and Company | 5.96 USD | 66.779% |
Bausch + Lomb Corporation | -0.74 USD | 367.568% |
Haemonetics Corporation | 2.32 USD | 14.655% |
Envista Holdings Corp | -0.60 USD | 430.0% |
ResMed Inc. | 6.94 USD | 71.47% |
Teleflex Incorporated | 7.58 USD | 73.879% |
Warby Parker Inc. | -0.54 USD | 466.667% |
West Pharmaceutical Services, Inc. | 7.99 USD | 75.219% |